Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16306241 | 0.91 | ITGB1 (0.42) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL22384162 | 0.90 | ITGB1 (0.39) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL22756228 | 0.90 | ITGB3 (0.40) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL19544621 | 0.89 | ITGB3 (0.41) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL19807126 | 0.89 | ITGB1 (0.40) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL22384275 | 0.88 | PLG (0.47) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL22756166 | 0.88 | ITGB1 (0.38) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL22756182 | 0.87 | ITGB3 (0.40) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL20900635 | 0.87 | PLG (0.41) | PLGITGB1ITGA4ITGB3ITGA2B | |
| SCHEMBL22756185 | 0.87 | KLKB1 (0.39) | PLGITGB1ITGA4ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PLG 3184/4885ITGB1 3589/4885ITGA4 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.